Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
84.61
-0.87 (-1.02%)
Oct 1, 2026, 2:56 PM EDT - Market open
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Mirum Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $145.79. The average 1-year stock price forecast is 72.31% higher than the current stock price, while the lowest is $118 (+39.46%) and the highest is $195 (+130.47%).
Price Target: $145.79 (+72.31%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 10 | 10 | 10 | 10 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $137 | Buy | Reiterates | $137 | +61.92% | Sep 29, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $123 → $130 | Buy | Maintains | $123 → $130 | +53.65% | Sep 29, 2026 |
| Citi | Citi | Buy Maintains $145 → $160 | Buy | Maintains | $145 → $160 | +89.10% | Sep 29, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $140 | Buy | Maintains | $140 | +65.47% | Sep 29, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $154 | Buy | Reiterates | $154 | +82.01% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
696.55M
from 521.31M
Increased by 33.62%
Revenue Next Year
819.52M
from 696.55M
Increased by 17.65%
EPS This Year
-15.14
from -0.47
EPS Next Year
-0.35
from -15.14
EPS and Forward PE are based on non-GAAP adjusted numbers.